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Bacillus Calmette-Guerin–Refractory or Relapsed
Non–Muscle-Invasive Bladder Cancer: A Phase II
Randomized Study
Neal D. Shore, Stephen A. Boorjian, Daniel J. Canter, Kenneth Ogan, Lawrence I. Karsh, TracyM. Downs, Leonard
G. Gomella, Ashish M. Kamat, Yair Lotan, Robert S. Svatek, Trinity J. Bivalacqua, Robert L. Grubb III, Tracey L.
Krupski, Seth P. Lerner, Michael E. Woods, Brant A. Inman, Matthew I. Milowsky, Alan Boyd, F. Peter Treasure,
Gillian Gregory, David G. Sawutz, Seppo Yla-Herttuala, Nigel R. Parker, and Colin P.N. Dinney
A B S T R A C T
Purpose
Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus
Calmette-Guerin (BCG) treatment ormay experience disease relapse.We assessed the efﬁcacy and safety
of recombinant adenovirus interferon alfawith Syn3 (rAd–IFNa/Syn3), a replication-deﬁcient recombinant
adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC.
Methods
In this open-label, multicenter (n = 13), parallel-arm, phase II study (ClinicalTrials.gov identiﬁer:
NCT01687244), 43 patients with HG BCG-refractory or relapsed NMIBC received intravesical rAd–IFNa/
Syn3 (randomly assigned 1:1 to 13 1011 viral particles (vp)/mLor 33 1011 vp/mL). Patientswho responded at
months3,6, and9were retreatedatmonths4,7, and10.Theprimaryendpointwas12-monthHGrecurrence-
free survival (RFS). All patients who received at least one dose were included in efﬁcacy and safety analyses.
Results
Forty patients received rAd–IFNa/Syn3 (1 3 1011 vp/mL, n = 21; 3 3 1011 vp/mL, n = 19) between
November 5, 2012, andApril 8, 2015. Fourteen patients (35.0%; 90%CI, 22.6% to49.2%) remained free of
HG recurrence 12months after initial treatment. Comparable 12-month HGRFSwas noted for both doses.
Of these 14 patients, two experienced recurrence at 21 and 28 months, respectively, after treatment
initiation, and one died as a result of an upper tract tumor at 17 months without a recurrence. rAd–IFNa/
Syn3 was well tolerated; no grade four or ﬁve adverse events (AEs) occurred, and no patient dis-
continued treatment because of an adverse event. The most frequently reported drug-related AEs
were micturition urgency (n = 16; 40%), dysuria (n = 16; 40%), fatigue (n = 13; 32.5%), pollakiuria
(n = 11; 28%), and hematuria and nocturia (n = 10 each; 25%).
Conclusion
rAd—IFNa/Syn3waswell tolerated. It demonstrated promising efﬁcacy for patients with HGNMIBC
after BCG therapy who were unable or unwilling to undergo radical cystectomy.
J Clin Oncol 35:3410-3416. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Non–muscle-invasive bladder cancer (NMIBC)
represents the most common disease state for
patients with newly diagnosed bladder cancer.1
Those with high-grade (HG) tumors are at sig-
niﬁcant risk for both recurrence and progression.2,3
Bacillus Calmette-Guerin (BCG) represents the
current preferred management.4-6 Nonetheless,
approximately 30% of patients will not respond to
BCG; among those who demonstrate an initial
response, more than 50% will experience re-
currence and progression during long-term
follow-up.7
The optimal management of patients with
persistent or recurrent tumor after BCG remains
controversial.8 Although radical cystectomy
provides cancer eradication,9 many patients are
elderly, have signiﬁcant comorbidities with an
attendant diminished performance status, and
often are unwilling to undergo radical extirpative
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surgery. Nonextirpative treatment options are available, but studies
to date have included relatively small patient numbers and used
varied deﬁnitions of treatment success8,10-16 Indeed, the US Food
and Drug Administration (FDA) and genitourinary oncology com-
munity agree that scant progress has beenmade in themanagement of
this disease since the initial approval of BCG.17-19 Thus an effective
alternative to radical cystectomy for patients with disease recurrence
after BCG treatment remains an important unmet clinical need.17
Recombinant intravesical interferon alfa-2b protein (IFNa-
2b; Intron A; Merck, Kenilworth, NJ) demonstrated promising
initial clinical results in NMIBC.20,21 Intravesical IFNa-2b gene
delivery offers a novel approach and increases the duration of
exposure to IFNa-2b. Recombinant adenovirus (rAd)–IFNa-2b is
a replication-deﬁcient adenovirus-based gene transfer vector that
encodes the human IFNa-2b gene.22-24 Syn3, a polyamide sur-
factant, is incorporated into the drug formulation (rAd–IFNa/
Syn3; Instiladrin, FKD Therapies Oy, Kuopio, Finland)25 to en-
hance adenoviral transduction of the bladder lining. Dramatic
enrichment of rAd–IFNa gene transfer and expression has been
shownwith Syn3 in both normal urothelium and human urothelial
carcinoma that grows in mice.22-25 rAd–IFNa-2b gene therapy
mimics the physiologic events associated with viral infection,
which results in local rather than systemic IFNa-2b production
and subsequent tumor regression.22
A phase I dose-ascending study of rAd–IFNa/Syn3 was per-
formed for patients with BCG-refractory and relapsing NMIBC.26
Dose-dependent adenoviral gene transfer and urine concentrations
of IFNa-2b were conﬁrmed. Of 14 patients treated with dose levels
of rAd–IFNa/Syn3 that resulted in measurable urine IFNa, six
(43%) were free from recurrence at 3 months and had no dose-
limiting toxicity, and two patients remained disease free at 29 and
39 months.26 These provocative ﬁndings, predominantly at the two
highest doses, prompted this phase II study, designed to evaluate the
efﬁcacy and safety of intravesical rAd–IFNa/Syn3 for patients with
HG NMIBC refractory to, or with relapse after, BCG.
METHODS
Study Design
This randomized, open-label, parallel-arm study was conducted across 13
centers in the United States between November 5, 2012, and April 8, 2015. The
protocol, administrative oversight, and accrual timelines were designed and
conducted by the Society of Urologic Oncology Clinical Trials Consortium.
The study protocol and informed consent formwere reviewed and approved
by the respective responsible site institutional review boards and biosafety
committees.
Patients
The trial was designed to enroll 40 patients unable or unwilling to
undergo radical cystectomy, and there were two dosage groups of 20
patients each. Eligible patients were 18 years or older and had HG BCG-
refractory or relapsed NMIBC, including papillary NMIBC alone (Ta or T1),
carcinoma in situ (CIS) alone, or a combination of CIS and papillary disease.
BCG-refractory disease was deﬁned as the inability to achieve a disease-free
state at 6 months after adequate induction BCG therapy with either
maintenance or reinduction at 3 months. Adequate induction was deﬁned as
a minimum of ﬁve of six treatments, and adequate maintenance was deﬁned
as a minimum of two of three treatments. BCG relapse was deﬁned as
recurrence within 1 year after a complete response to adequate BCG treatment (at
least ﬁve and two instillations). Patients were required to have undergone visually
complete resection of papillary lesions by transurethral resection of bladder
tumors. Patients could not have received intravesical therapy within 3 months
before beginning study treatment, with the exception of cytotoxic agents when
administered as a single instillation immediately after a transurethral resection. All
participants who entered the study provided written or oral informed consent.
Random Assignment and Masking
Patients were assigned by computer-generated random assignment, with
a constrained 1:1 sequence, to receive either low-dose (1 3 1011 viral particles
[vp]/mL) or high-dose (33 1011 vp/mL) rAd–IFNa/Syn3. These doses were the
most promising observed in the phase I study. The total doses administeredwere
7.53 1012 vp in the low-dose group and 2.253 1013 vp in the high-dose group.
Treatment allocation was performed centrally with a block size of two for all
patients who had successfully completed screening, with the constraint that
the ﬁrst four patients at each site were balanced between cohorts.
Procedures
rAd–IFNa/Syn3 in 75 mL was administered intravesically through
a urethral catheter, with a planned retention time of 1 hour; an anticholinergic
treatment was allowed to relieve urinary urgency and permit adequate re-
tention. Patients without recurrence of HG disease at months 3, 6, and 9, as
evaluated by cytology, cystoscopy, and biopsy (if clinically indicated) were then
retreated at months 4, 7, and 10. At 12 months, a ﬁnal efﬁcacy evaluation was
performed. This evaluation included a protocol-mandated biopsy from the site
of the index tumor and at least ﬁve random biopsies, including the bladder
dome, trigone, right and left lateral wall, posterior wall, and prostatic urethra in
men with positive cytology or prior disease in this region.
During the study, patients were contacted weekly by phone for the
ﬁrst month after each treatment on days 7, 14 (of months 7 and 10 only), 21,
and 28 (6 1 day) to provide information about adverse events (AEs) and
concomitant medication use. Assessments for treatment failure were made
between 14 and 7 days before retreatment. Patients whowere withdrawn from
treatment before study completion underwent a safety assessment at least
30 days after last administration of the study drug. All patients are being
monitored in a 3-year long-term follow-up period to (1) determine re-
currence of HG disease in those patients with a complete response and (2) to
assess the long-term impact of treatment with rAd–IFNa/Syn3.
End Points
The primary end point was freedom from HG disease recurrence at
12 months, deﬁned by a negative for cause or end of study biopsy. Sec-
ondary end points included response to treatment, deﬁned as no evidence
of recurrence of HG disease at 3, 6, and 9 months; incidence and time to
cystectomy; and concentration of IFNa-2b in the urine. Safety assessments
included physical examination, monitoring of vital signs, ECG, and standard
clinical chemistry, hematology, and urinalysis assessments (performed by local
laboratories). Safety end points include type, incidence, relatedness, and se-
verity of AEs and severe ($ grade 3) AEs (SAEs), as assessed byNational Cancer
Institute Common Terminology Criteria for Adverse Events (version 4.03).
Statistical Analyses
We determined that a cohort of 20 patients would be sufﬁcient to give
an 80% probability of rejection of a HG recurrence-free survival (RFS) rate
of 10% with an exact 5% one-sided test when the true HG RFS rate was
35%. The operating characteristics for this Fleming design were cal-
culated exactly with the binomial distribution described by A’Hern.27 The
hypothesis—that the response rate was equal to or less than the reference
rate—was rejected if ﬁve or more of the 20 patients achieved HG RFS at
12 months. The proportion of patients who achieved HG RFS at 3, 6, 9, and
12 months was reported for each dose group, together with an exact 90% CI
for the proportion. The time to HG recurrence or death was summarized
with the Kaplan-Meier method. Analyses were performed with SAS (version
9 or later; SAS Institute, Cary, NC). Both the safety and efﬁcacy (modiﬁed
jco.org © 2017 by American Society of Clinical Oncology 3411
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intention-to-treat) analysis sets included all patients who received at least one
dose of rAd–IFNa/Syn3. A data monitoring committee oversaw the study
according to the data monitoring plan.
Analytical Assays and Sample Testing
All analytical assays were developed and validated. Samples were
tested according to good laboratory practices methods at Covance Lab-
oratories Ltd (Harrogate, United Kingdom). Description of the assays and
the results of sample testing are presented in the Appendix (online only).
RESULTS
Patient disposition is shown in Figure 1. Baseline characteristics are
listed in Table 1.
Primary End Point: HG RFS
The12-month HGRFS rate was comparable between the two dose
groups, with 33.3%of patients (7 of 21; 90%CI, 16.8 to 53.6) in the low-
dose group and 36.8% (7 of 19; CI, 18.8 to 58.2) in the high-dose group
alive and free of HGdisease at 12months. Overall, 35.0%of patients (14
of 40; 90% CI, 22.6% to 49.2%) remained free of HG recurrence at
12 months after the initiation of rAd–IFNa/Syn3 treatment (Table 2).
Off-schedule disease assessments did not affect ﬁndings (Appendix,
online only). The median time to HG recurrence or death was
6.5 months (90% CI, 3.52 to 12.78 months); the median time to HG
recurrence was 3.52 months (90% CI, 3.02 to 12.78 months) for the
low-dose group and was 11.73 months (90% CI, 5.88 months to not
evaluable) for the high-dose group.
When patient subgroups and secondary end points were
considered in exploratory analyses, the 12-month HG RFS rates
were broadly similar for men and women, for younger and older
patients, for refractory or relapsed NMIBC, for CIS only or
papillary tumors and CIS, and for patients with Ta and T1 disease
only (Table 2). Interestingly, of the 14 patients whowere recurrence
free at 12 months, 10 (71%) of the 14 had an antiadenovirus an-
tibody response (deﬁned as four times the predose titer), compared
with 11 (24%) of 25 who experienced recurrence.
Signiﬁcant levels of urine IFNa-2b were measurable in all
patients in month 1 at days 2, 4, and 12 (Table 3). Of those patients
who received a second dose, measurable IFNa-2b urine concen-
trations were noted in month 4 on days 2 and 4 after drug adminis-
tration. Urine IFNa-2b concentrations did not appear to correlate with
dose or clinical response.
In long-term follow-up, seven patients (18%) who withdrew
from the study because of HG disease recurrence within the 12-
month study period died at a median of 16 months (range, 2 to
26 months) after the withdrawal date. There is no indication that
these deaths were treatment related. The cause of death was un-
known in four patients, whereas two died as a result of progressive
bladder cancer and one died as a result of liver failure unrelated to
treatment 17 months after withdrawal from the study. The four
patients for whom the cause of death is unknown were being
observed locally after they completed their end-of-study evalua-
tion. Fourteen patients (35%) who experienced an HG recurrence
within the ﬁrst year underwent a radical cystectomy at a median of
9 months (range, 4 to 28 months) from day 1 of month 1.
Patients are being monitored for 3 years to collect long-term
follow-up data. Of the 14 patients who remained disease free at
12 months, additional follow-up data are being collected for 11; 3
withdrew from the study. Nine of these 11 patients are alive, and eight
remained disease-free during a period of 15 to more than 36 months
(Table 4). Two patients experienced HG recurrence at 21 and
28 months, respectively, from the start of treatment. One of these
patients who experienced progression to muscle invasion underwent
a radical cystectomy 31 months after the initiation of treatment and
later died at 41 months. The other, who experienced recurrence at
Assigned 1 × 1011 vp/mL dose
(n = 22)
Assigned 3 × 1011 vp/mL dose
(n = 21)
Withdrawn before dosing
(n = 1)
(n = 1)
Patient did not meet 
   inclusion criteria
Completed study (n = 8) (n = 9)
(n = 10)
(n = 9)
(n = 1)(n = 13)
Did not complete study 
   because of disease 
     recurrence
Completed study
Did not complete study
Disease recurrence
Patient request
Included in safety and 
efficacy analysis sets
(n = 21)
Included in safety and 
efficacy analysis sets
(n = 19)
Withdrawn before dosing (n = 2)
(n = 1)
(n = 1)
Patient had event of 
   pulmonary edema
Patient did not meet
   inclusion criteria
Enrolled and 
randomly assigned
(N = 43)
Fig 1. Patient dispositions. vp, viral particles.
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21 months, remained alive and free from distant recurrence at
36 months. One patient free from bladder recurrence at 12 months
died as a result of an upper tract tumor at 17 months.
Safety End Points
Overall, 39 patients (97.5%) experienced AEs during the
study; 20 patients (95%) were in the low-dose arm, and 19 patients
(100%) were in the high-dose arm (Data Supplement). In 34 of
these patients (85%), at least one AE was considered to be drug
related;: in 18 (87.5%) of 21 patients in the low-dose arm and in 16
(84.2%) of 19 patients in the high-dose arm. The most frequently
reported drug-related AEs were micturition urgency in 16 patients
(40%), dysuria in 16 patients (40%), fatigue in 13 patients (32.5%),
pollakiuria in 11 patients (28%), hematuria and nocturia in 10
patients each (25% each). Notably, for the majority of patients
(78%), the AEs were transient and classiﬁed as either grade 1 or 2.
Nine patients (22%) reported a total of 19 grade 3 AEs: 12 in the low-dose
arm (coronary artery occlusion, diarrhea, sepsis, arthralgia, renal neo-
plasm, transitional cell carcinoma, carotid artery occlusion, syncope,
renal failure, nephroureterectomy, COPD, and hypotension) and
seven in the high-dose arm (abdominal pain, back pain, fracture,
syncope, dysuria [n = 2], and acute renal failure; Data Supplement).
Although coded as A’s according to convention, the renal neoplasm,
transitional cell carcinoma, and nephroureterectomy reports in the
low-dose arm reﬂect the diagnosis and treatment of a separate upper
tract urothelial carcinoma in one patient. All grade 3 AEs occurred
only once. There were no grade 4 or 5 events.
Overall, ﬁve patients exhibited a total of 10 SAEs: three patients
had a total of eight SAEs in the low-dose group, and two patients had
a total of two SAEs in the high-dose group. Of these, one episode of
diarrhea (low-dose group; treated with 1,000 mL of 0.9% sodium
chloride intravenously) and one episode of acute renal failure (high-
dose group; urine culture, 59,000 to 99,000 colony-forming units/mL
of Klebsiella pneumoniae; treated with antibiotics) were considered
related to the study drug. Both resolved with medical therapy.
There was no signiﬁcant difference in the initial occurrence of AEs
in those who received the low or high dose of rAd–IFNa/Syn3.
DISCUSSION
We report the results from a completed phase II trial of intravesical
rAd–IFNa/Syn3 for patients with recurrent NMIBC after BCG.
Several important ﬁndings emerge from the resultant data set, in-
cluding a 12-monthHGRFS of 35% by intention-to-treat analysis of
all patients dosed. Notably, responses were durable: the majority
remained disease-free for close to 24 months. We noted a 30%
durable complete response for patients with any element of CIS and
a 50% RFS for patients with papillary disease only at study entry.
Likewise, the 12-month RFS in heavily pretreated patients was 31%.
rAd–IFNa/Syn3 treatment was well tolerated; there were no grade 4
or 5 events, and no patients discontinued treatment because of drug-
related AEs. Analytical assays indicated that IFNa-2b was mea-
surable in the urine of all patients, which provided evidence for
effective adenoviral-mediated gene transfer. Bioassays revealed no
evidence for rAd–IFNa DNA in the blood, which provided addi-
tional reassurance for biosafety.
Several agents have been evaluated as second-line treatment
after BCG; however, none (to date) have provided robust and
durable responses. Valrubicin (Valstar; Endo Pharmaceuticals,
Malvern, PA), the only agent currently approved by the FDA for
the treatment of BCG-refractory CIS, provided a complete
response rate of 18% at 6 months and a 1-year disease-free
survival rate of approximately 10%.16 Promising results from
early-phase trials have been reported for intravesical taxane and
gemcitabine.10-14 Joudi et al15 reported the ﬁnal results from
a national multicenter phase II trial of BCG plus IFNa-2b and
noted that 45% of patients with BCG failure were free from
recurrence at 2 years. However, only 44% were treated for an
HG recurrence, and 61% received only one prior course of
BCG.15 A recent retrospective analysis of BCG and IFNa-2b
reported a 38.6% RFS at 12 months. Again, many of these
patients (20 of 44) received only one prior course of BCG, and
16 patients experienced relapse after 12 months.27 Overall, the
limited number of patients studied in previous trials, as well as
the modest RFS with treatment despite a less stringently deﬁned
eligibility, illustrates the unmet need for effective and evidence-
based second-line therapy for patients with BCG-unresponsive
Table 1. Baseline Patient Characteristics
Characteristic
No. (%) by rAd–IFNa/Syn3 Dose
Group
No. (%)
Overall
(N = 40)
1 3 1011 vp/mL
(n = 21)
3 3 1011 vp/mL
(n = 19)
Median (IQR) age,
years
70 (67-74) 73 (62-81) 70.5 (64.5-77.5)
Sex
Male 19 (90) 14 (73.7) 33 (82.5)
Female 2 (9.5) 5 (26.3) 7 (17.5)
ECOG PS
0 16 (76.2) 18 (94.7) 34 (85.0)
1 5 (23.8) 1 (5.3) 6 (15.0)
History of radiation
therapy*
1 (4.8) 1 (5.3) 2 (5)
BCG failure
classiﬁcation
Relapsed 10 (47.6) 9 (47.4) 19 (47.5)
Refractory 11 (52.4) 10 (52.6) 21 (52.5)
No. of previous BCG
courses
1 1 1 2
2 10 12 22
$ 3† 10 6 16
Primary tumor
classiﬁcation at
enrollment
CIS 12 (57.1) 9 (47.4) 21 (52.5)
Ta 2 (9.5) 2 (10.5) 4 (10)
Ta and CIS 3 (14.3) 1 (5.3) 4 (10)
T1 2 (9.5) 4 (21.1) 6 (15)
T1 and CIS 2 (9.5) 3 (15.8) 5 (12.5)
Abbreviations: BCG, bacillus Calmette-Guerin; CIS, carcinoma in situ; ECOG PS,
Eastern Cooperative Oncology Group performance status; IQR, interquartile
range; rAd–IFNa/Syn3, recombinant adenovirus interferon alfa protein/Syn3 (a
nonreplicating recombinant adenovirus gene transfer vector for patients with
high-grade BCG-refractory or relapsed non–muscle-invasive bladder cancer); Ta,
papillary urothelial carcinoma conﬁned to the mucosa; T1, micro-invasive uro-
thelial carcinoma invasive into lamina propria but not muscularis propria; vp, viral
particles.
*Radiotherapy was 10 or more years before screening in each of these three
patients; as such, they were deemed eligible for study enrollment.
†Range of previous courses, 3 to 8.
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disease that improves disease-speciﬁc patient outcomes and avoids
cystectomy.
We recognize that this study is limited by its relatively small
sample size and the lack of a comparative treatment arm. However,
the trial was designed to determine optimal dosing and to provide
preliminary efﬁcacy to develop a deﬁnitive single-arm registration
study.12 Few agents have actually gone beyond phase I and II
development, so it is readily apparent that the traditional pathway
for drug registration does not work for NMIBC. This concern was
addressed through deliberations among the Society of Urologic
Oncology, American Urological Association, and FDA, with the
consensus that a single-arm trial with a mixed population of papillary
disease and CIS was appropriate for the BCG-unresponsive pop-
ulation, given that a minimal threshold of patients who had some
component of CIS was met.17
Although the clinical impact of rAd–IFNa is encouraging,
the mechanisms that mediate its antitumor activity remain un-
deﬁned. In preclinical studies, IFNa and rAd–IFN beta inhibited
angiogenesis,28,29 and IFNa directly induced apoptosis in human
bladder cancer cells by inducing autocrine tumor necrosis
factor–related apoptosis-inducing ligand production.30 Fur-
thermore, rAd–IFNa overcame resistance to the IFNa protein
in vitro and in animal models.22 It is now well established that
IFNa controls dendritic cell maturation and antigen presentation
and promotes tumor recognition by T cells and natural killer cells,
and that these effects likely play more important roles in tumor
growth inhibition than the direct effects of IFNa on tumor
cells.31-33 Like IFN gamma, IFNa induces programmed death
ligand 1 expression,34 which may limit tumor immune recog-
nition and almost certainly inhibits T-cell activation; this may
Table 2. Incidence of HG RFS at 3, 6, 9, and 12 Months
Variable
rAd–IFNa/Syn3 Dose Group
Overall
(N = 40)
1 3 1011 vp/mL
(n = 21)
3 3 1011 vp/mL
(n = 19)
No. (%) of Patients 90% CI (%)* No. (%) of Patients 90% CI (%)* No. (%) of Patients 90% CI (%)*
RFS at secondary end point analysis time
3 months 10 (47.6) 28.6 to 67.2 13 (68.4) 47.0 to 85.3 23 (57.5) 43.3 to 70.8
6 months 8 (38.1) 20.6 to 58.3 9 (47.4) 27.4 to 68.0 17 (42.5) 29.2 to 56.7
9 months 8 (38.1) 20.6 to 58.3 9 (47.4) 27.4 to 68.0 17 (42.5) 29.2 to 56.7
12 months 7 (33.3) 16.8 to 53.8 7 (36.8) 18.8 to 58.2 14 (35.0) 22.6 to 49.2
HG recurrence-free subgroup at 12 months
Refractory NMIBC (n = 31) 8 (38.1) 20.6 to 58.3
Relapsed NMIBC (n = 19) 6 (31.6) 14.7 to 53.0
CIS only (n = 21) 6 (28.6) 13.2 to 48.7
Papillary tumor (n = 9) 3 (33.3) 9.7 to 65.6
Ta + T1 disease only (n = 10) 5 (50.0) 22.2 to 77.8
Serum antiadenoviral antibody
Positive (n = 22) 10 (45.5) 27.1 to 64.7
Negative (n = 17) 4 (23.5) 8.5 to 46.1
Abbreviations: CIS, carcinoma in situ; HG, high-grade; NIMBC, non–muscle-invasive bladder cancer; rAd–IFNa/Syn3, recombinant adenovirus interferon alpha protein/
Syn3 (a nonreplicating recombinant adenovirus gene transfer vector for patients with high-grade bacillus Calmette-Guerin–refractory or relapsed NMIBC); RFS, relapse-
free survival; Ta; papillary urothelial carcinoma conﬁned to themucosa; T1: micro invasive urothelial carcinoma invasive into lamina propria but not muscularis propria; vp,
viral particles.
*CI is for the proportion of patients with HG RFS; 90% CIs are based on the exact binomial method.
Table 3. Urinary IFNa-2b Concentrations After Treatment With rAd–IFNa/Syn3
Visit
Patients With Measurable Urinary IFNa-2b Concentrations
Range of Urinary IFNa-2b Concentrations
(IU/mL) for Patients With Measurable IFNa-2b*
No. of Patients
% in Dose Group 1
(n = 40)
% in Dose Group 2
(n = 23)
In Dose Group 1
(n = 40)
In Dose Group 2
(n = 23)
M1D1 0 0 0
M1D2 40 100 247-68,255
M1D4 34 85 118-91,441
M1D12 7 18 34-922
M4D1 0 0 0
M4D2 17 74 54-11,587
M4D4 8 35 34-1,329
M4D12 0 0 0
Abbreviations: IFNa-2b, interferon alfa-2b protein; MID1, month 1 day 1; M1D2, month 1 day 2; M1D4, month 1 day 4; M1D12, month 1 day 12; M4D1, month 4 day 1;
M4D2, month 4 day 2; M4D4, month 4 day 4; M4D12, month 4 day 12; rAd–IFNa/Syn3, recombinant adenovirus interferon alfa protein/Syn3 (a nonreplicating
recombinant adenovirus gene transfer vector for patients with high-grade bacillus Calmette-Guerin–refractory or relapsed non–muscle-invasive bladder cancer).
*Urinary IFNa-2b concentrations were measured by ELISA. Concentrations were measured over 2 dosing cycles and the data are presented as both the number of
patients with measurable IFNa-2b concentrations in each dosing cycle and the range of measurable protein concentrations in IU/mL.
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explain the resistance to rAd–IFNa by some of the bladder cancers
treated in this study. Combination therapy with IFNa and an
anti–programmed death 1 inhibitor was more efﬁcacious in
preclinical studies than either agent alone at inhibition of
melanoma tumor growth, and combination trials in NMIBC are
under consideration.34 Finally, studies have demonstrated that
local delivery of IFNa is better than systemic delivery to enhance
tumor immune recognition, and viral transduction itself pro-
vides an important signal for kickstarting the immune system.
Thus, in addition to serving as a bioreactor for sustained IFNa
production (in contrast to the transient levels measured after
intravesical instillation of the IFNa protein),24 IFNa gene therapy
should produce unique, desirable effects on antitumor immunity
through local (as opposed to systemic) IFNa production and viral
activation of intracellular pattern receptors. Thus, there are multiple
reasons to explain the enhanced efﬁcacy of rAd–IFNa compared
with IFNa-2b in the treatment of refractory NMIBC.35
In summary, rAd–IFNa/Syn3 was well tolerated and dem-
onstrated promising efﬁcacy for patients with HG NMIBC after
BCG therapy. A phase III trial of high-dose rAd–IFNa/Syn3, which
provided longer median HG RFS and equivalent biosafety, is
ongoing.
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Appendix
Supplemental Methods
Role of the funding source. FKD Therapies Oy (Kuopio, Finland) provided funding to the investigators for study design, conduct,
treatment administration, and data collection. The study database was held by the funder. All authors had unrestricted access to the raw
and ﬁnal study data andwere responsible for data interpretation, the preparation of the report, and the decision to submit for publication.
Recombinant Adenovirus Interferon Alfa Protein/Syn3 production. First-generation replication-deﬁcient serotype 5 adenovirus
vector, which expressed human interferon alfa-2b (IFNa-2b) cDNA under a cytomegalovirus promoter, was produced under good
manufacturing practice conditions in 293 cells, as previously described,1 with slight modiﬁcations of the process. It was tested to be
free of endotoxin, microbiologic contaminants, and other impurities. The structure of the vector was veriﬁed by sequencing.
Production of recombinant IFNa-2b was veriﬁed from each production lot with immunologic methods. The excipient Syn3 is
a polyamide surfactant that enhances adenoviral gene transfer to the bladder epithelium.2,3
Analytical Assays
Sample collections and assay methods. Whole blood and urine samples were collected on days 1 (predose), 2, 4, and 12 of
months 1 and 4 for measurement of recombinant adenovirus IFNa-2b (rAd–IFNa-2b) DNA and IFNa-2b concentrations (urine
only). Serum samples for IFNa-2b protein concentration measurements also were collected on days 1 (predose), 2, 4, and 12 of
months 1 and 4. Serum samples for antibody assays were collected before dosing on day 1 of months 1, 4, 7, and 10, as well as at the
month-13/withdrawal visit.
Urine samples for rAd–IFNa-2b DNA, IFNa-2b, and exploratory assays were collected into a sterile container and stabilized
with the addition of buffer that contained 10% bovine serum albumin and 50 mMof HEPES (pH, 7.4). TwomL of buffer was added
to each 20-mL sample of urine as soon as possible after collection of the urine sample. After addition of the stabilization buffer,
aliquots were transferred into 2-mL cryotubes by using sterile pipette tips and were put on ice. Whole-blood samples for de-
termination of rAd–IFNDNA by polymerase chain reaction (PCR) were collected into EDTA-containing tubes. Blood samples were
collected at the required time points, were divided into sterile polypropylene cryotubes with sterile pipette tips, and were frozen
at 270°C until shipment for analysis. Whole-blood samples for serum IFNa-2b measurements and for determination of anti-
adenoviral and anti–IFNa-2b antibodies were drawn at the required time points. The samples were drawn into red top Vacutainer
(Becton, Dickinson, and Co., Franklin Lakes, NJ) tubes and allowed to clot at room temperature for 30 minutes. The samples were
then centrifuged at 4°C,3 1,500 g, for 15 minutes, and the serumwas separated into cryovials. All samples for all assays were frozen
at 270°C within 5 hours of collection and were stored for shipment and analysis.
IFNa-2b protein concentration assay. Measurement of IFNa-2b concentrations in urine and serum samples was done by ELISA
with a MesoScale discovery platform (Meso Scale Diagnostics, Bethesda, MD). Samples were incubated with a master mix to allow
IFNa-2b to bind to biotinylated-anti–IFNa antibodies and sulfo-tagged (sTag)–anti-IFNa antibodies to form an antibody-bridge
complex. After incubation, samples were added to the streptavidin-coated plate. The biotinylated–anti-IFNa antibodies bound to
the streptavidin-coated plate, which allowed any unboundmaterial to be washed away. Read buffer that contained tripolyamine was
added. The sTag associated with anti-IFNa antibodies produced a chemiluminescent signal when an electrical voltage was applied.
The concentration of IFNa-2b in samples was then back-calculated from a calibration curve. The method had a lower level of
quantiﬁcation of 31 IU/mL and an upper level of quantiﬁcation of 2,000 IU/mL.
Analytical assays for rAd–IFNa DNA in blood and urine. To assess systemic exposure and urinary concentrations of rAd–IFNa
vector DNA, a sensitive and speciﬁc quantitative PCR (qPCR) assay for the vector DNAwas developed and validated. In both assay
matrices, ampliﬁcation was detected in all replicates of the standard curve (13 109 viral particles [vp]/225 ml to 13 103 vp/225 ml
for all valid runs), and the correlation coefﬁcient of the dilutions (R2) was greater than or equal to 0.98 for all qPCRs performed. An
assessment of the speciﬁcity of the qPCR assay was made with human and Escherichia coli DNA. No cross reactivity with either
matrix was observed when 1-, 0.5-, and 0.1-mg templates were present in the qPCR assay. To determine if either human or E. coli
DNA could interfere with the accuracy of the qPCR assay, a spike of 2 3 103 vp/2 ml of rAd–IFNa DNA (derived from the
appropriate matrix matched standard) was spiked into a background of each concentration of genomic DNA.
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Anti-IFN a antibody assay. Assessment of anti-IFNa antibody concentrations was done with a validated human anti-IFNa
platinum ELISA from Affymetrix eBioscience (product code BMS217TEN; Thermo Fisher Scientiﬁc, Waltham, MA) with a mouse
monoclonal anti-IFNa antibody as the positive control. The assay paradigm was a quasi-quantitative assay sequence that consisted
of a screening assay to determine whether a positive signal existed, a competitive inhibition conﬁrmation assay of the positive signal,
and a titration assay that used serially diluted samples in buffer.
Antiadenovirus type 5 antibody assay. Antiadenovirus type 5 antibody concentrations were measured in serum from each
patient with an ELISA-based assay. Serum samples from a predose dilution series were assessed for antiadenovirus antibodies to
establish the baseline titer for each patient. Serumwas diluted to the predose titer, and then 1:2 and 1:4 dilutions of the predose titer
dilution were made for sample testing at each time point. Antibodies then were measured at the predose titer and in each dilution.
In this quasi-quantitative assay, antibody titer results greater than twice the predose titer were considered signiﬁcant.
Supplemental Results
Sensitivity analysis of primary end point. To assess the impact of off-schedule disease assessments on the primary efﬁcacy end
point, a sensitivity analysis was conducted in which 12 months was deﬁned according to the assessment date as opposed to the
nominal month-13 assessment. Results for the sensitivity analysis were identical to the primary efﬁcacy end point: 14 of 40 patients
(35%) overall showed high-grade recurrence free survival at 12 months and experienced comparable incidences for the dose groups
(low-dose: n = 7 of 21 [33%]; high-dose: n = 7 of 19 [37%]).
IFNa-2b serum concentrations. Serum IFNa-2b concentrations were low. At day 2 of month 1, 31 of the 40 patients had
concentrations less than 31 IU/mL (limit of assay quantiﬁcation). Six patients had concentrations greater than 31 IU/mL but less
than 50 IU/mL, and two patients had concentrations greater than 50 IU/mL but less than 160 IU/mL.
Blood and Urine rAd–IFNa DNA measurements. Median blood and urine concentrations of rAd DNAwere measured
with a qPCR assay that had a level of detection of 13 103 vp/225 mL. Importantly, no measurable rAd–IFNa DNAwas detected in
blood after the initial dosing. Of the 23 patients who received a second dose at month 4, only one patient (4.3%), randomly assigned
to the 33 1011 vp/mL dose group, had a positive test result for a low level of virus detected at day 2 of month 1 (7.73 103 vp/225mL),
which was not measurable by day 4 of month 1.
As expected, all 40 patients had signiﬁcant copies of rAd DNA in their urine at day 2 of month 1; the median value was 1.133
106 vp/225 mL. Thirty-nine patients had measurable concentrations of rAd DNA copies at day 4 of month 1. However, these were
approximately three orders of magnitude lower; the median value was 8.08 3 104 vp/225 mL. Thirty-three patients (85%) had
measurable concentrations at day 12 of month 1, and the median value was 2.3 3 104 vp/225 mL. In the 23 patients who received
a second dose of rAd–IFN, 22 had measurable concentrations of rAd DNA at day 2 of month 4 and a median value of 5.133 105 vp/
225 mL, and 20 patients had measurable concentrations of approximately eight times the level of detection at day 4 of month 4 and
amedian value of 8.453 103 vp/225mL. By day 12 of month 4, only six patients (29%) hadmeasurable copies of rAd–IFNaDNA in
the urine. Results for the two dose cohorts were comparable.
Anti-IFNa antibody and antiadenovirus antibody concentrations. Anti–IFNa-2b antibody concentrations in serum
were measured in serum from each patient. With the sole exception of one patient who had a weak 1:20 titer at day 12 of month 1,
no other patient at any time point had measurable anti–IFNa-2b antibodies. Antiadenovirus type 5 antibody concentrations were
measured in serum from each patient with a quasi-quantitative assay (see Covance Laboratories, Harrogate, UK for details).
Antibody data were collected at days 1 and 12 of month 1, day 1 of month 7, day 1 of month 10, and at the month-13/
withdrawal assessment. The data demonstrated that 22 patients (55.0%) had a signiﬁcant antiadenovirus antibody response
(deﬁned as four times the predose titer). Of the 14 patients who experienced a complete response, 10 (71%) had a signiﬁcant
antiadenovirus antibody response, and four (29%) did not demonstrate a signiﬁcant response. These data suggest that a signiﬁcant
antiadenovirus vector antibody response does not appear to correlate with lack of efﬁcacy. A deﬁnitive antibody titer for any of the
positive patients was not determined.
Safety
A summary of all treatment-emergent adverse events is provided in the Data Supplement.
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